No Data
An Intrinsic Calculation For Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) Suggests It's 24% Undervalued
Here's Why Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Can Manage Its Debt Responsibly
Zhejiang Wolwo Bio-Pharmaceutical's Q3 Profit Rises 1%
Obu Biotech: Report for the third quarter of 2024
zhejiang wolwo bio-pharmaceutical (300357.SZ) profit distribution plan for the first three quarters of 2024: proposed 1 yuan dividend per 10 shares.
Gelonghui October 23rd | Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that, in order to actively reward the vast investors and comprehensively consider the funds needed for the sustainable development of the company and the reasonable return to investors, the profit distribution plan for the first three quarters of 2024 was approved by the ninth meeting of the fifth Board of Directors. Based on the total share capital of 523,584,000 shares as of September 30, 2024, the company will distribute a cash dividend of RMB 1.00 per 10 shares to all shareholders, totaling RMB 52,358,400.00 (tax included), without bonus shares or capital reduction.
Zhejiang Wolwo Bio-pharmaceutical (300357.SZ) released its performance for the first three quarters, with a net income of 0.272 billion yuan, a year-on-year increase of 0.78%.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) 29% Price Boost Is Out Of Tune With EarningsNo Data
No Data
